Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service bridge-to-transplant program for patients with heart failure

DOI: 10.1016/j.healun.2014.01.003
Journal of Heart and Lung Transplantation, 2014, 33, 350-8.

#	Paper	IF	Citations
34	HeartWare beats HeartMate II, but choice still not clear. *PharmacoEconomics & Outcomes News*, **2014**, 698, 5-5	0.1	
33	Economic evaluation in health care: a modern day quagmire. *Journal of Heart and Lung Transplantation*, **2014**, 33, 344-6	5.8	0
32	Impact of age on outcomes following continuous-flow left ventricular assist device implantation. *Interactive Cardiovascular and Thoracic Surgery*, **2015**, 20, 743-8	1.8	14
31	Cardiac surgery 2014 reviewed. *Clinical Research in Cardiology*, **2015**, 104, 1006-20	6.1	6
30	Left ventricular assist devices-current state and perspectives. *Journal of Thoracic Disease*, **2016**, 8, E660-6	2.6	66
29	Biological Cardiac Assist Devices. *Learning Materials in Biosciences*, **2016**, 169-198	0.3	
28	Tissue Engineering for the Heart. *Learning Materials in Biosciences*, **2016**,	0.3	
27	CASE 13-2016 Minimally Invasive Left Ventricular Assist Device Insertion Without Cardiopulmonary Bypass. *Journal of Cardiothoracic and Vascular Anesthesia*, **2016**, 30, 1716-1726	2.1	5
26	A Systematic Review of the Cost-Effectiveness of Long-Term Mechanical Circulatory Support. *Value in Health*, **2016**, 19, 494-504	3.3	14
25	Cardiac replacement therapies: outcomes and costs for heart transplantation versus circulatory assist. *Scandinavian Cardiovascular Journal*, **2017**, 51, 1-7	2	11
24	Long-term prognosis and cost-effectiveness of left ventricular assist device as bridge to transplantation: A systematic review. *International Journal of Cardiology*, **2017**, 235, 22-32	3.2	20
23	Cost-utility analysis of direct ventricular assist device vs double bridges to heart transplantation in patients with refractory heart failure. *Clinical Transplantation*, **2017**, 31, e13124	3.8	5
22	The In-Hospital Cost of Ventricular Assist Device Therapy: Implications for Patient Selection. *ASAIO Journal*, **2017**, 63, 725-730	3.6	4
21	Survival After Orthotopic Heart Transplantation in Patients Undergoing Bridge to Transplantation With the HeartWare HVAD Versus the Heartmate II. *Annals of Thoracic Surgery*, **2017**, 103, 1505-1511	2.7	29
20	Cost-effectiveness of left ventricular assist devices for patients with end-stage heart failure: analysis of the French hospital discharge database. *ESC Heart Failure*, **2018**, 5, 75-86	3.7	17
19	Cost-effectiveness analysis in cardiac surgery: A review of its concepts and methodologies. *Journal of Thoracic and Cardiovascular Surgery*, **2018**, 155, 1671-1681.e11	1.5	7
18	Impact of Sharing O Heart With Non-O Recipients: Simulation in the United Network for Organ Sharing Registry. *Annals of Thoracic Surgery*, **2018**, 106, 1356-1363	2.7	2

17	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2018**, 20, 1505-1535	12.3	285
16	The Effect of Total Cost Information on Consumer Treatment Decisions: An Experimental Survey. *Medical Decision Making*, **2018**, 38, 584-592	2.5	3
15	Surgical Approaches in Heart Failure. *Critical Care Nursing Clinics of North America*, **2019**, 31, 267-283	1.5	2
14	Elective or emergency heart transplantation: Cost comparison in a single center. *Clinical Transplantation*, **2019**, 33, e13596	3.8	3
13	Why is There Discordance between the Reimbursement of High-Cost Life-Extending Pharmaceuticals and Medical Devices? The Funding of Ventricular Assist Devices in Australia. *Applied Health Economics and Health Policy*, **2019**, 17, 421-431	3.4	2
12	A Systematic Review of Cost-Effectiveness Analyses of Left Ventricular Assist Devices: Issues and Challenges. *Applied Health Economics and Health Policy*, **2019**, 17, 35-46	3.4	6
11	Quality of economic evaluations of ventricular assist devices: A systematic review. *International Journal of Technology Assessment in Health Care*, **2020**, 1-8	1.8	0
10	Statistics of heart failure and mechanical circulatory support in 2020. *Annals of Translational Medicine*, **2020**, 8, 827	3.2	14
9	Comparative assessment of different versions of axial and centrifugal LVADs: A review. *Artificial Organs*, **2021**, 45, 665-681	2.6	3
8	Health-Economic Aspects of MCS Therapy. **2017**, 595-603		
7	MCS Candidate Selection Criteria. **2017**, 37-58		
6	Mechanical Circulatory Support. *Advances in Medical Technologies and Clinical Practice Book Series*, 800-823	0.3	
5	Conflicting findings between the Mitra-Fr and the Coapt trials: Implications regarding the cost-effectiveness of percutaneous repair for heart failure patients with severe secondary mitral regurgitation. *PLoS ONE*, **2020**, 15, e0241361	3.7	1
4	How to cope with a temporarily aborted transplant program: solutions for a prolonged waiting period. *Annals of Translational Medicine*, **2015**, 3, 306	3.2	2
3	Are Medical Devices Cost-Effective?. *Applied Health Economics and Health Policy*, **2021**, 1	3.4	0
2	Ex-vivo lung perfusion therapies. *Current Opinion in Organ Transplantation*, **2022**, Publish Ahead of Print,	2.5	0
1	Commentary: Cost-Effectiveness of Left Ventricular Assist Devices as Destination Therapy in the United Kingdom. *Frontiers in Cardiovascular Medicine*, 9,	5.4	